Coulter Partners places Life Sciences Industry Veteran as CFO at Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.

Commenting on the collaboration with Coulter Partners, Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune, said:

“Coulter Partners impressed us with their life sciences expertise, professionalism, and urgency, delivering top candidates and ensuring the best fit. We're pleased to have partnered with them.”